Welcome Reception

Bay Lawn 

Breakfast & Registration 

 

Welcome & introduction
Gareth Morgan & Ola Landgren 

Session 1: Genomics and epigenomics 2025
Chairs: Gareth Morgan & Leif Bergsagel

• The genetic basis for racial disparity in MM: Kylee MacLachlan 
• The transcriptional  mechanism of action of NSD2: Yubao Wang 
• Apoptotic profiling of t(4:14) MM: Lawrence Boise 
• Epigenetic features of t(4;14) MM: Benjamin Barwick 
• The genetic basis and origin of MM: Francesco Maura  
• Structural variation in MM in depth analysis of PDX model: Brian Walker
• Mind the gap in the MM genome: Aneta Mikulasova

 

Panel discussion: Using genomic targets in MM

Break

Session 2: Resistance mechanisms
Chairs: Benjamin Diamond & Niels Weinhold

• Tumor intrinsic resistance mechanisms to immunotherapy: Michael Durante 
• Lenalidomide resistance: Charlotte Pawlyn
• Transcriptional resistance and MM as a superenhanceropathy: Leif Bergsagel
• Focal and breakout lesions in the evolution of resistance: Niels Wienhold 
• Biallelic antigen escape is a recurrent mechanism of resistance to anti-CD38 antibodies: Ben Diamond

Panel discussion: addressing drug resistance

Session 3: Biological models and single cell analyses                                                               
Chairs: Charlotte Pawlyn & Felipe Prósper

• Novel insights from the Vk*MYC mouse model: Marta Chesi
• Modeling MM genetic and immune heterogeneity in nice: José Ángel Martínez–Climent
• Complex human bone marrow organoids for the study of  MM: Sarah Gooding
• Epigenetic drivers of disease progression: Felipe Prósper 
• Genomic profiling of Precursor Disease; Bachisio Ziccheddu
• Immune microenvironment and resistance to therapy: Madhav Dhodapkar

 

Panel discussion: future strategies for myeloma management

Lunch

Session 4: Update on MRD as a clinical endpoint
Chairs:  Ola Landgren & Dickran Kazandjian

 

Panel discussion

Session 5: Clinical trial updates
Chairs: Adriana Rossi & Rafael Fonseca

• Emerging approaches for use of bispecific antibodies in precursors: Ola Landgren
• The emerging role of belantamab mafodotin: Rafael Fonseca 
• Efficacy and safety of isatuximab combinations frontline and at relapse MM: Thomas Martin 
• Daratumamab combinations their current and future role: Dickran Kazandjian

 

Panel discussion: questions for clinical trials

Break

Session 6: Clinical and Translational Research with MMRF
Chairs: George Mulligan & Hearn Cho

• The HORIZON Adaptive trial platform: Nitya Nathwani
• Translational studies of the MyDrug trial MEKi arm: Chuck Acharya
• Tumor and microenvironment insights from Immune Atlas: Reyka Jayasinghe

 

Panel Discussion

Closing remarks 

Welcome and Introductions

Keynote Lecture 

Chair: Niels Weinhold

The spatio-temporal evolution of multiple myeloma: Leo Rasche

 

Panel discussion 

Session 7:  Novel Targets
Chairs: Faith Davies  & Arun Wiita                                                                             

• The role of allogeneic BCMA-targeting CAR-T cells in RRMM: Sham Mailankody  
• Novel approaches to targeting RAS as a potential clinical therapy: Faith Davies 
• CAR T cells targeting novel membrane-based antigens: Arun Wiita 
• Novel biomarkers for guiding the use of immunotherapies: Frank Zhan

 

Panel discussion: developing novel targets for the clinic

Break

Session 8: Optimizing T-Cell Engaging therapy in the clinic: data session

Part 1: Bispecifics

Chairs: Damian Green & Yi Lin

 

 

Overview lecture:
Novel resistance mechanisms for bispecific antibodies in MM: Nizar Bahlis

• The current and future use of teclistamab: Saad Usmani
• The current use and development of talquetamab; Ciara Freeman
• Update on the clinical data using elranatamab; Nizar Bahlis
• Latest progress with Linvoseltamab: Gareth Morgan
• Progress with the novel optimized bispecific ABBV-383: Rachid Baz
• Optimizing BCMA as a therapeutic target; Damian Green

 

Panel discussion: Optimizing the use of Bispecifics in the clinic 

 

Lunch

Part 2: CAR-T

Chairs: Adam Cohen & Ciara Freeman

• The development and application of ADC for use in MM: Hans Lee
• Developing the use and application of the current licenced Car T cell therapies: Adam Cohen
• The development and potential of Anito-cel; Matthew J. Frigault
• Update on the use of allogeneic anti-BCMA CAR-T CB-011: Adriana Rossi
• Exploiting innovative CAR-T designs and targets: Yi Lin

 

Panel discussion: Optimizing the use of CAR-T in the clinic

Summary & closing remarks of iwMyeloma 2025

Gareth Morgan & Ola Landgren

iwMyeloma Scientific Committee: 

Gareth Morgan (Co-Chair) USA, Ola Landgren (Co-Chair) USA
Ken Anderson USA, Leif Bergsagel USA, Irene Ghobrial USA, Sagar Lonial USA, Maria Victoria Mateos Spain, Jesus San Miguel Spain, Pieter Sonneveld NL, Keith Stewart Canada